RxDoctor Payments Data

Skyler Sharp

Family · Woodstock, VANPI 1538619473

Payments from drug & device makers

$1,072in general payments, 2019–2025

Across 64 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$345
  • Lilly USA, LLC$172
  • Pfizer$167
  • AstraZeneca$92
  • Merck$72
  • Amgen$56
  • plus $168 from 6 others

What the payments were for

  • Food & beverage$1,072100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,072 in reported general payments places this provider in the 70th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$1,375
Medicare patients
13
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$64,504
EliquisApixaban34$34,644
RybelsusSemaglutide13$19,410
MounjaroTirzepatide14$17,066
XareltoRivaroxaban24$13,158
JanumetSitagliptin Phos/Metformin Hcl13$7,027
Breo ElliptaFluticasone/Vilanterol12$6,273
Advair HfaFluticasone Propion/Salmeterol12$5,188
Bevespi AerosphereGlycopyrrolate/Formoterol Fum11$4,035
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,136
Atorvastatin Calcium195$1,794
Levothyroxine Sodium118$1,634
Omeprazole87$1,461
Clonidine13$996
Losartan Potassium78$937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$345$83,91460 claims
PfizerEliquis$167$34,64434 claims
Lilly USA, LLCMounjaro$172$17,06614 claims
Johnson & JohnsonXarelto$31$13,15824 claims
MerckJanumet$72$7,02713 claims
GSKBreo Ellipta$17$6,27312 claims
AstraZenecaBevespi Aerosphere$92$4,03511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,332 family providers in Virginia.

Other family in Woodstock

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →